Shares of Stemline Therapeutics Inc (NASDAQ:STML) have received an average rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $33.75.
STML has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Stemline Therapeutics in a report on Friday, February 2nd. BidaskClub cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 19th. Zacks Investment Research cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Finally, ValuEngine cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday.
Shares of Stemline Therapeutics (STML) opened at $18.50 on Friday. The firm has a market cap of $509.91, a P/E ratio of -7.20 and a beta of -0.07. Stemline Therapeutics has a 1-year low of $7.30 and a 1-year high of $18.50.
In related news, CEO Ivan Bergstein sold 3,820 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $15.80, for a total value of $60,356.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Kenneth Hoberman sold 11,983 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $14.18, for a total transaction of $169,918.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 103,317 shares of company stock worth $1,637,383. 16.70% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Royce & Associates LP purchased a new position in Stemline Therapeutics in the fourth quarter valued at approximately $106,000. Two Sigma Investments LP purchased a new position in Stemline Therapeutics in the fourth quarter valued at approximately $170,000. Voya Investment Management LLC purchased a new position in Stemline Therapeutics in the second quarter valued at approximately $102,000. MetLife Investment Advisors LLC purchased a new position in Stemline Therapeutics in the fourth quarter valued at approximately $186,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Stemline Therapeutics in the fourth quarter valued at approximately $189,000. Institutional investors own 50.39% of the company’s stock.
WARNING: “Stemline Therapeutics Inc (STML) Receives Consensus Rating of “Hold” from Analysts” was published by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://theenterpriseleader.com/2018/04/02/stemline-therapeutics-inc-stml-receives-consensus-rating-of-hold-from-analysts.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.